VICL


Here’s Why Vical (VICL) Shares Took a 30% Plunge Today

Nothing can kill a healthcare’s stock price like a failed clinical trial. Just take a look at the disaster that’s befallen Vical Incorporated …

Vical Incorporated (VICL) Announces Last Patient Completed Assessment In Phase 3 HCT Trial

Vical Incorporated (NASDAQ:VICL) announced that the last patient completed their final assessment during the one year follow-up period in the multinational Phase 3 …

Analysts Dive in on Two Volatile Biotech Stocks: Sarepta Therapeutics Inc (SRPT), Vical Incorporated (VICL)

It has been an explosive twenty-four hours in the biotech-verse, as analysts are prompted to offer insights on Sarepta Therapeutics Inc (NASDAQ:SRPT), with shares shooting …

Company Update (NASDAQ:VICL): Vical Incorporated and Astellas Announce Topline Results from a Phase 2 Study of CMV Vaccinein Kidney Transplant Patients

Vical Incorporated (NASDAQ:VICL) announced topline results from a randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety and efficacy of cytomegalovirus (CMV) vaccine, …

Stock Update (NASDAQ:VICL): FDA Grants Vical Incorporated Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis

Vical Incorporated (NASDAQ:VICL), a biotechnology company developing vaccines and therapeutics for prevention and treatment of infectious diseases, announced that the U.S.

Company Update (NASDAQ:VICL): Vical Incorporated Reports Third Quarter 2015 Financial Results and Progress in Key Development Programs

Vical Incorporated (NASDAQ:VICL) reported financial results for the three and nine months ended September 30, 2015. Net loss for the third quarter of 2015 …

Company Update (NASDAQ:VICL): Vical Incorporated to Present Preclinical Data at ICAAC 2015 Meeting

Vical Incorporated (NASDAQ:VICL), a biotechnology company developing vaccines and therapeutics for prevention and treatment of infectious diseases, today announced that the Company will present …

Stock Update (NASDAQ:VICL): FDA Grants QIDP Designation to VL-2397, Vical Incorporated’s Antifungal Product Candidate

Vical Incorporated (NASDAQ:VICL), a biotechnology company developing vaccines and therapeutics for prevention and treatment of infectious diseases, today announced that the U.S.

Vical Incorporated Clinical Setback; 2 Analysts With Different Views

Vical Incorporated (NASDAQ:VICL) shares are tumbling 42.85% to $0.

Roth Capital Reiterates Buy on Vical Incorporated Ahead of Upcoming HSV-2 Data Release

Roth Capital analyst Debjit Chattopadhyay came out with a research note on Vical Incorporated (NASDAQ:VICL), as the company is expected to release top-line …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts